DECA-DURABOLIN Drug Patent Profile
✉ Email this page to a colleague
When do Deca-durabolin patents expire, and when can generic versions of Deca-durabolin launch?
Deca-durabolin is a drug marketed by Woodward Specl and is included in one NDA.
The generic ingredient in DECA-DURABOLIN is nandrolone decanoate. There are fifteen drug master file entries for this compound. Additional details are available on the nandrolone decanoate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DECA-DURABOLIN?
- What are the global sales for DECA-DURABOLIN?
- What is Average Wholesale Price for DECA-DURABOLIN?
Summary for DECA-DURABOLIN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 15 |
Clinical Trials: | 2 |
Patent Applications: | 5 |
DailyMed Link: | DECA-DURABOLIN at DailyMed |
Recent Clinical Trials for DECA-DURABOLIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Morten Tange Kristensen PT, PhD | Phase 2 |
University Hospital Ostrava | N/A |
US Patents and Regulatory Information for DECA-DURABOLIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Woodward Specl | DECA-DURABOLIN | nandrolone decanoate | INJECTABLE;INJECTION | 013132-001 | Jun 12, 1986 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Woodward Specl | DECA-DURABOLIN | nandrolone decanoate | INJECTABLE;INJECTION | 013132-002 | Jun 12, 1986 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Woodward Specl | DECA-DURABOLIN | nandrolone decanoate | INJECTABLE;INJECTION | 013132-003 | Jun 12, 1986 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |